skip to main content

Brivaracetam – SV2A Mechanism and LEV Interaction — SCE Neurology MCQ

Instant feedback + full explanation. One question, done properly.

HardEpilepsy & Seizure DisordersBrivaracetam – SV2A Mechanism and LEV InteractionSCE Neurology

A 48-year-old man with known epilepsy on lacosamide and levetiracetam presents with a breakthrough seizure. His neurologist considers adding brivaracetam. What is the relationship between brivaracetam and levetiracetam?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Brivaracetam is a selective, high-affinity SV2A ligand — the same molecular target as levetiracetam but with higher affinity and selectivity; combining them is generally not recommended

Brivaracetam is a selective synaptic vesicle protein 2A (SV2A) ligand — the same molecular target as levetiracetam — but with approximately 15–30x higher affinity. Because they share the same target, combining brivaracetam with levetiracetam is generally not recommended (no additional benefit from dual SV2A targeting). If adding brivaracetam, levetiracetam should typically be withdrawn. Brivaracetam may cause fewer behavioural side effects than levetiracetam. A: They share the SV2A target. C: Brivaracetam acts primarily on SV2A. D: It is not a prodrug. E: It is not a GABA-A agonist.

Reference: Brivaracetam SmPC; NICE NG217 (2025); BNF